share_log

Aurora Cannabis | 6-K: Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility

Aurora Cannabis | 6-K: Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility

極光大麻 | 6-K:極光大麻獲得德國工廠擴大種植和獨特研究許可
美股SEC公告 ·  2024/07/25 14:13

Moomoo AI 已提取核心訊息

Aurora Cannabis Inc. has been granted two licenses by Germany's Federal Institute for Drugs and Medical Devices (BfArM) under the new Medical Cannabis Act. The expanded cultivation license allows Aurora to continue domestic production and add an approved product, while a dedicated R&D license permits trials of up to seven novel cultivars at their EU GMP facility in Leuna.Since 2021, Aurora's Leuna facility has been producing approximately 1,000 kg of medical cannabis flower annually under a tender agreement with BfArM. The new licenses reflect Aurora's commitment to quality and compliance, positioning the company to meet growing patient demand in Germany's expanding medical cannabis market.Michael Simon, President of Aurora Europe, emphasized the company's leadership in the region and its dedication to providing high-quality cannabis. Aurora views these developments as part of a broader trend towards medical cannabis acceptance and regulatory reform across Europe, aligning with their global strategy to improve patient access to medical cannabis.
Aurora Cannabis Inc. has been granted two licenses by Germany's Federal Institute for Drugs and Medical Devices (BfArM) under the new Medical Cannabis Act. The expanded cultivation license allows Aurora to continue domestic production and add an approved product, while a dedicated R&D license permits trials of up to seven novel cultivars at their EU GMP facility in Leuna.Since 2021, Aurora's Leuna facility has been producing approximately 1,000 kg of medical cannabis flower annually under a tender agreement with BfArM. The new licenses reflect Aurora's commitment to quality and compliance, positioning the company to meet growing patient demand in Germany's expanding medical cannabis market.Michael Simon, President of Aurora Europe, emphasized the company's leadership in the region and its dedication to providing high-quality cannabis. Aurora views these developments as part of a broader trend towards medical cannabis acceptance and regulatory reform across Europe, aligning with their global strategy to improve patient access to medical cannabis.
Aurora大麻股公司已經獲得德國聯邦藥品和醫療設備研究所(BfArM)根據新的醫療大麻法案頒發的兩個許可證。擴展的種植許可證允許Aurora繼續國內生產並增加一款已獲批准的產品,而專門的研發許可證則允許在它們位於Leuna的歐盟GMP設施中試驗多達七個新型品種。自2021年以來,Aurora的Leuna設施在與BfArM的招標協議下每年生產約1000公斤醫療大麻花。這些新許可證反映了Aurora對質量和合規性的承諾,使公司能夠滿足德國不斷增長的醫療大麻市場中患者的需求。Aurora歐洲區總裁Michael Simon強調了公司在該地區的領導地位及其提供高質量大麻的決心。Aurora將這些發展視爲整個歐洲對醫療大麻接受度和監管改革的更廣泛趨勢的一部分,與他們的戰略相一致,以改善患者獲取醫療大麻的途徑。
Aurora大麻股公司已經獲得德國聯邦藥品和醫療設備研究所(BfArM)根據新的醫療大麻法案頒發的兩個許可證。擴展的種植許可證允許Aurora繼續國內生產並增加一款已獲批准的產品,而專門的研發許可證則允許在它們位於Leuna的歐盟GMP設施中試驗多達七個新型品種。自2021年以來,Aurora的Leuna設施在與BfArM的招標協議下每年生產約1000公斤醫療大麻花。這些新許可證反映了Aurora對質量和合規性的承諾,使公司能夠滿足德國不斷增長的醫療大麻市場中患者的需求。Aurora歐洲區總裁Michael Simon強調了公司在該地區的領導地位及其提供高質量大麻的決心。Aurora將這些發展視爲整個歐洲對醫療大麻接受度和監管改革的更廣泛趨勢的一部分,與他們的戰略相一致,以改善患者獲取醫療大麻的途徑。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息

    聲明

    本頁的譯文內容由軟件翻譯。 Moomoo將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。